stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) P/B ratio
As of 5 November 2026, ICON PLC (ICLR) trades at a P/B ratio of 1.7×. Over the past ten years it has ranged from 0.7× (February 2026) to 7.4× (September 2021); the current reading is higher than 14% of that period. That is below the Diagnostics & Research industry median of 3.4× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.6× | (15.16%) |
| FY2024 | 1.8× | (26.57%) |
| FY2023 | 2.5× | 34.32% |
| FY2022 | 1.9× | (27.91%) |
| FY2021 | 2.6× | (53.75%) |
| FY2020 | 5.6× | (0.46%) |
| FY2019 | 5.6× | 8.38% |
| FY2018 | 5.2× | (0.76%) |
| FY2017 | 5.2× | 19.14% |
| FY2016 | 4.4× | (26.99%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.4× | 0.66% |
| Jun 2026 | 1.4× | 56.21% |
| Mar 2026 | 0.9× | (41.38%) |
| Dec 2025 | 1.6× | 7.16% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| ICLR ICON PLC | 1.7× |
| RVTY Revvity Inc. compare | 2.3× |
| QGEN QIAGEN N.V. compare | 3.1× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| CRL Charles River Laboratories International, Inc. compare | 4.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| MEDP Medpace Holdings, Inc. compare | 30.3× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement